Back to top
more

Biocept, Inc. (BIOC)

(Delayed Data from NSDQ)

$0.91 USD

0.91
317,349

+0.01 (1.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assure Holdings Corp. (IONM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -28.57% and 17.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agiliti (AGTI) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Agiliti (AGTI) delivered earnings and revenue surprises of 5.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Sotera Health Company (SHC) delivered earnings and revenue surprises of 4.55% and 1.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

InnovAge Holding Corp. (INNV) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Misses Q2 Earnings Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Quest Diagnostics (DGX) Expands Testing Suite With NGS Test

by Zacks Equity Research

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

What Makes Biocept (BIOC) a New Buy Stock

by Zacks Equity Research

Biocept (BIOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biocept (BIOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Biocept (BIOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session

by Zacks Equity Research

Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.

    5 Medtech Stocks to Steer Clear of Amid Political Chaos

    by Zacks Equity Research

    In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.

      Teladoc November Visits Set Record: Why is Stock Suffering?

      by Zacks Equity Research

      Teladoc Inc. (TDOC), the first and the largest telehealth company disclosed that the month of November witnessed a total of 101,600 patient visits.